All In Biotech

Drug Trial Radar · NCT00925002

Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis

OPEN-LABEL SAFETY AND EFFICACY EVALUATION OF FX-1006A IN SUBJECTS WITH TRANSTHYRETIN (TTR) AMYLOIDOSIS

Last checked: Nov 20, 2026Latest source record: Jul 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

93

Actual

Start

Aug 5, 2009

Primary completion

Jul 8, 2020

Study completion Jul 8, 2020

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 19, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label study designed to obtain additional long-term safety and efficacy data for oral tafamidis (20 mg soft gelatin capsule) administered once daily (QD). In addition, this study continued to provide tafamidis to Val30Met subjects who had completed Protocol Fx-006 (a 1-year, open-label extension study to Protocol Fx-005 which was a randomized, double-blind, placebo-controlled, 18-month study to evaluate the safety and efficacy of tafamidis) or non-Val30Met subjects who had completed Protocol Fx1A-201 (a Phase 2, open-label study to evaluate TTR stabilization, safety, and tolerability of tafamidis) for up to 10 years or until subjects had access to tafamidis for ATTR-PN via prescription. Upon regulatory approval for the treatment of ATTR-PN in their respective country and access to prescription tafamidis, subjects may have been withdrawn from the study. Such subjects were considered study completers.

Conditions

  • ATTR-PN

Interventions

  • TafamidisDrug

    20 mg oral Fx-1006A daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Val30Met Group: Neuropathy Impairment Score Lower Limb (NIS-LL) Score at BaselineTime frame: Baseline (i.e. last measurement prior to first dose) of B3461020 (Fx-005)
  2. Val30Met Group: Change From B3461020 Baseline in Neuropathy Impairment Score Lower Limb (NIS-LL) Score at Month 30Time frame: Baseline (i.e. last measurement prior to first dose) of B3461020 (Fx-005), Month 30
  3. Val30Met Group: Change From B3461020 Baseline in Neuropathy Impairment Score Lower Limb (NIS-LL) Score at Month 66Time frame: Baseline (i.e. last measurement prior to first dose) of B3461020 (Fx-005), Month 66
  4. NonVal30Met Group: Neuropathy Impairment Score Lower Limb (NIS-LL) Score at BaselineTime frame: Baseline (i.e. last measurement prior to first dose) of B3461022 (Fx1A-201)
  5. NonVal30Met Group: Change From B3461022 Baseline in Neuropathy Impairment Score Lower Limb (NIS-LL) Score at Month 12Time frame: Baseline (i.e. last measurement prior to first dose) of B3461022 (Fx1A-201), Month 12
  6. NonVal30Met Group: Change From B3461022 Baseline in Neuropathy Impairment Score Lower Limb (NIS-LL) Score at Month 60Time frame: Baseline (i.e. last measurement prior to first dose) of B3461022 (Fx1A-201), Month 60
  7. Val30Met Group: Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at BaselineTime frame: Baseline of B3461020 (Fx-005)
  8. Val30Met Group: Change From B3461020 Baseline in Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at Month 30Time frame: Baseline of B3461020 (Fx-005), Month 30
  9. Val30Met Group: Change From B3461020 Baseline in Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at Month 66Time frame: Baseline of B3461020 (Fx-005), Month 66
  10. NonVal30Met Group: Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at BaselineTime frame: Baseline of B3461022 (Fx1A-201)
  11. NonVal30Met Group: Change From B3461022 Baseline in Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at Month 12Time frame: Baseline of B3461022 (Fx1A-201), Month 12
  12. NonVal30Met Group: Change From B3461022 Baseline in Total Quality of Life (TQOL) Score Assessed Using Norfolk Quality of Life for Diabetic Neuropathy (QOL-DN) Questionnaire at Month 60Time frame: Baseline of B3461022 (Fx1A-201), Month 60
  13. Val30Met Group: Karnofsky Performance Scale (KPS) Score at Month 30Time frame: Month 30 (Baseline of B3461023)
  14. Val30Met Group: Karnofsky Performance Scale (KPS) Score at Month 66Time frame: Month 66 (Month 36 of B3461023)
  15. NonVal30Met Group: Karnofsky Performance Scale (KPS) Score at BaselineTime frame: Baseline of B3461022 (Fx1A-201)
  16. NonVal30Met Group: Change From B3461022 Baseline in Karnofsky Performance Scale (KPS) Score at Month 12Time frame: Baseline of B3461022 (Fx1A-201), Month 12
  17. NonVal30Met Group: Change From B3461022 Baseline in Karnofsky Performance Scale (KPS) Score at Month 60Time frame: Baseline of B3461022 (Fx1A-201), Month 60
  18. Val30Met Group: Number of Participants by Ambulation Stage at BaselineTime frame: Baseline of B3461020 (Fx-005)
  19. Val30Met Group: Number of Participants by Ambulation Stage at Month 30Time frame: Month 30
  20. Val30Met Group: Number of Participants by Ambulation Stage at Month 66Time frame: Month 66
  21. NonVal30Met Group: Number of Participants by Ambulation Stage at BaselineTime frame: Baseline of B3461022 (Fx1A-201)
  22. NonVal30Met Group: Number of Participants by Ambulation Stage at Month 12Time frame: Month 12
  23. NonVal30Met Group: Number of Participants by Ambulation Stage at Month 60Time frame: Month 60

Locations

9 sites in 8 countries. Site status is shown where the registry gives one.

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • FLENI

    Buenos Aires, Argentina

  • Hospital Universitário Clementino Fraga Filho -HUCFF Universidade Federal do Rio de Janeiro

    Rio de Jameiro, R.J., Brazil

  • Centre d'Investigation Clinique

    Créteil, France

  • Universitatsklinikum Muenster

    Münster, Germany

  • Centro per lo Studio e la Cura delle Amiloidosi Sistemiche IRCCS - Policlinico San Matteo

    Pavia, Italy

  • Centro Hospitalar Lisboa Norte, EPE- Hospital de Santa Maria

    Lisbon, Portugal

  • Unidade Clinica de Paramiloidose Centro Hospitalar do Porto, EPE - Hospital Geral de Santo António

    Porto, Portugal

  • FAP-Teamet Familjar Amyloidos

    Umeå, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.